We promote the understanding of assessment and access processes for life science products to support the development and adoption of innovative treatments
Germany's Health Ministry has proposed a two-stage AMNOG pathway that would allow selected medicines to receive an initial benefit assessment on the best available evidence, followed by reassessment after further evidence has been generated.
France has agreed a new medicines pricing framework that combines more favourable launch pricing for selected innovative products with earlier and more systematic price reviews over the product lifecycle.
France will stop reimbursing low-clinical-benefit medicines at 100% solely because they are prescribed for a long-term condition, leaving the standard 15% reimbursement rate to apply from October.
